Join Growin Stock Community!

Intensity therapeutics, inc.INTS.US Overview

US StockHealthcare
(No presentation for INTS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

INTS AI Insights

INTS Overall Performance

INTS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INTS Recent Performance

-0.78%

Intensity therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

INTS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

INTS Key Information

INTS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

INTS Profile

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Price of INTS

INTS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INTS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.73
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.73
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is INTS's latest earnings report released?

    The most recent financial report for Intensity therapeutics, inc. (INTS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INTS's short-term business performance and financial health. For the latest updates on INTS's earnings releases, visit this page regularly.

  • How much cash does INTS have?

    At the end of the period, Intensity therapeutics, inc. (INTS) held Total Cash and Cash Equivalents of 7.07M, accounting for 0.74 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is INTS's EPS continuing to grow?

    According to the past four quarterly reports, Intensity therapeutics, inc. (INTS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INTS?

    Intensity therapeutics, inc. (INTS)'s Free Cash Flow (FCF) for the period is -2.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 39.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INTS?

    The latest valuation data shows Intensity therapeutics, inc. (INTS) has a Price-To-Earnings (PE) ratio of -2.48 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.